Bayesian Capital Management, LP Aim Immuno Tech Inc. Transaction History
Bayesian Capital Management, LP
- $838 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding AIM
# of Institutions
36Shares Held
9.01MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.33MShares$866,0000.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$397,7400.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$139,6530.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$92,8030.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il458KShares$91,5530.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $9.61M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...